Provenge is among a new class of experimental drugs called "therapeutic cancer vaccines," which are designed to train the immune system to recognize and attack the body's own abnormal cells.
It failed to prove effective in one Phase III study among a wide range of prostate cancer patients, including those with late-stage disease that had spread to other parts of the body.
Market Data 
Markets 
AI
